SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-043568
Filing Date
2024-05-15
Accepted
2024-05-15 16:02:03
Documents
92
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205793-10q_elevai.htm   iXBRL 10-Q 838228
2 CERTIFICATION ea020579301ex31-1_elevai.htm EX-31.1 9894
3 CERTIFICATION ea020579301ex31-2_elevai.htm EX-31.2 10085
4 CERTIFICATION ea020579301ex32-1_elevai.htm EX-32.1 3896
  Complete submission text file 0001213900-24-043568.txt   5670915

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE elab-20240331.xsd EX-101.SCH 74125
6 XBRL CALCULATION FILE elab-20240331_cal.xml EX-101.CAL 41336
7 XBRL DEFINITION FILE elab-20240331_def.xml EX-101.DEF 308144
8 XBRL LABEL FILE elab-20240331_lab.xml EX-101.LAB 503051
9 XBRL PRESENTATION FILE elab-20240331_pre.xml EX-101.PRE 303610
96 EXTRACTED XBRL INSTANCE DOCUMENT ea0205793-10q_elevai_htm.xml XML 639693
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41875 | Film No.: 24950172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)